Drawing for LEGEND BIOTECH

USPTO serial 98880290

LEGEND BIOTECH

Reviewed by CopyMark Law Group

Reg. 7890671Status 700Registered
Filing date
Status date
Registration date
Aug 12, 2025
Examiner
MCMORROW, RONALD G
Law office
FILE REPOSITORY (FRANCONIA)

What this means

Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.

Status 700: Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six.

Need help with LEGEND BIOTECH?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Preetha Chakrabarti

Preetha Chakrabarti Crowell & Moring LLP375 Ninth AvenueTwo Manhattan WestNew York, NY 10001

Goods and services

ClassDescriptionStatusFirst use
005Pharmaceuticals and medical preparations for autoimmune diseases, non-communicable diseases, cancer or tumor, or infectious diseases; sanitary preparations for medical purposes; dietetic food and substances adapted for medical use; biological preparations for medical purposes, namely, autoimmune diseases, non-communicable diseases, cancer or tumor, or infectious diseases; biological tissue cultures for medical purposes; chemical preparations for medical purposes, namely, autoimmune diseases, non-communicable diseases, cancer or tumor, or infectious diseases; chemical preparations for pharmaceutical purposes, namely, autoimmune diseases, non-communicable diseases, cancer or tumor, or infectious diseases; drugs for medical purposes, namely, autoimmune diseases, non-communicable diseases, cancer or tumor, or infectious diseases; immunostimulants; medicines for human purposes, namely, autoimmune diseases, non-communicable diseases, cancer or tumor, or infectious diseases; pharmaceutical preparations, namely, autoimmune diseases, non-communicable diseases, cancer or tumor, or infectious diseases; Pharmaceutical compositions for autoimmune diseases, non-communicable diseases, cancer or tumor, or infectious diseases; pharmaceuticals for autoimmune diseases, non-communicable diseases, cancer or tumor, or infectious diseases; stem cells for medical purposes; Injectable pharmaceuticals for autoimmune diseases, non-communicable diseases, cancer or tumor, or infectious diseases; anti-cancer drugs; Anti-cancer preparations; Compounds for treating cancer; Pharmaceutical preparations and substances for the treatment of cancer; Anti-cancer preparations from hormones and antagonists; Biopharmaceuticals for the treatment of cancer; Biological preparations for the treatment of cancer; Pharmaceutical preparations for the treatment of cancer; Pharmaceutical products for the treatment of cancer; Pharmaceutical preparations and substances for the prevention of cancer; Cell growth media for growing cells for medical use; Cells for medical use, Living cells for medical use; vaccine preparation; Medical diagnostic preparationsACTIVE—
042Scientific and technological services, namely, scientific research, analysis, and testing in the field of biotechnology and scientific research and design relating thereto; design and development of computer hardware and software; biological research; chemical analysis; chemical research; chemistry services namely research in the field of chemistry; Scientific research in the nature of conducting clinical trials for others; culturing of cells for scientific research purposes, for others; medical research; research and development of new products for others; scientific laboratory services; scientific research; technological research in the field of biotechnology; Cell separation technology research services; Cell separation research services; Cell culture services for scientific and research purposes, for others; Scientific services relating to the isolation and cultivation of human tissues and cells for scientific and research purposes; Scientific research for medical purposes in the area of cancerous diseases; Stem cell research services; Antibody research and development; Pharmaceutical research and development; Medical computer programmingACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Jul 6, 2026TCCATEAS CHANGE OF CORRESPONDENCE RECEIVED—
Jul 6, 2026ARAAATTORNEY/DOM.REP.REVOKED AND/OR APPOINTEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Jul 6, 2026REAPTEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED—
Jul 6, 2026CHANAPPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED—
Jul 6, 2026COARTEAS CHANGE OF OWNER ADDRESS RECEIVED—
Aug 12, 2025NRCCNOTICE OF REGISTRATION CONFIRMATION EMAILED—
Aug 12, 2025R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Jun 24, 2025NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Jun 24, 2025PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Jun 18, 2025NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
May 22, 2025CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
May 21, 2025DOCKASSIGNED TO EXAMINER—
Dec 2, 2024NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Dec 2, 2024NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance